Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 10/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068120 | 0.85 | CRBN (0.46) | JAK2GRM2ALOX5APFEN1 | |
| SCHEMBL29348378 | 0.79 | JAK2 (0.40) | JAK2GRM2ALOX5APPDE10A | |
| SCHEMBL29348385 | 0.78 | ALOX5AP (0.38) | JAK2GRM2ALOX5AP | |
| SCHEMBL29348407 | 0.77 | PDCD1 (0.33) | JAK2GRM2 | |
| SCHEMBL29348423 | 0.76 | NR1I2 (0.35) | JAK2GRM2 | |
| SCHEMBL29348421 | 0.75 | CRBN (0.47) | JAK2 | |
| SCHEMBL31068312 | 0.75 | CRBN (0.47) | JAK2 | |
| SCHEMBL31068149 | 0.74 | CRBN (0.46) | JAK2 | |
| SCHEMBL31068109 | 0.74 | CRBN (0.46) | JAK2 | |
| SCHEMBL29348386 | 0.74 | CRBN (0.46) | JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |